Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1284-1290, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (44)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarke, G. M.
Right arrow Articles by Higgins, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarke, G. M.
Right arrow Articles by Higgins, T. N.
Related Collections
Right arrow Arnold O. Beckman Conference
Right arrow Hematology
(Clinical Chemistry. 2000;46:1284-1290.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Laboratory Investigation of Hemoglobinopathies and Thalassemias: Review and Update

Gwendolyn M. Clarke1 and Trefor N. Higginsa,1

1 Dynacare Kasper Medical Laboratories, 14940 123rd Ave., Edmonton, Alberta T5V 1B4, Canada.
a Author for correspondence. Fax 780-452-8488; e-mail higgins{at}dkml.com

Structural hemoglobin (Hb) variants typically are based on a point mutation in a globin gene that produce a single amino acid substitution in a globin chain. Although most are of limited clinical significance, a few important subtypes have been identified with some frequency. Homozygous Hb C and Hb S (sickle cell disease) produce significant clinical manifestations, whereas Hb E and Hb D homozygotes may be mildly symptomatic. Although heterozygotes for these variants are typically asymptomatic, diagnosis may be important for genetic counseling. Thalassemia, in contrast, results from quantitative reductions in globin chain synthesis. Those with diminished ß-globin chains are termed ß-thalassemias, whereas those with decreased {alpha}-chain production are called {alpha}-thalassemias. Severity of clinical manifestations in these disorders relates to the amount of globin chain produced and the stability of residual chains present in excess. The thalassemia minor syndromes are characterized clinically by mild anemia with persistent microcytosis. Thalassemia intermedia (i.e., Hb H disease) is typified by a moderate, variably compensated hemolytic anemia that may present with clinical symptoms during a period of physiologic stress such as infection, pregnancy, or surgery. The thalassemia major syndromes produce severe, life-threatening anemia. {alpha}-Thalassemia major usually is incompatible with extrauterine life; ß-thalassemia major presents in infancy and requires life-long transfusion therapy and/or bone marrow transplantation for successful control of the disease. Double heterozygosity for certain structural variants and/or thalassemia syndromes may also lead to severe clinical disease. Several guidelines have been published that outline the required steps for hemoglobinopathy and thalassemia investigation. The availability of HPLC has streamlined many of these requirements, allowing an efficient stepwise diagnostic strategy for these complex disorders.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
P. Kleinert, M. Schmid, K. Zurbriggen, O. Speer, M. Schmugge, B. Roschitzki, S. S. Durka, U. Leopold, T. Kuster, C. W. Heizmann, et al.
Mass Spectrometry: A Tool for Enhanced Detection of Hemoglobin Variants
Clin. Chem., January 1, 2008; 54(1): 69 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J Trop PediatrHome page
S. M. AlFadhli, A. M. Al-Awadhi, and D. AlKhaldi
Validity Assessment of Nine Discriminant Functions Used for the Differentiation between Iron Deficiency Anemia and Thalassemia Minor
J Trop Pediatr, April 1, 2007; 53(2): 93 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
R. A Thurlow, P. Winichagoon, T. Green, E. Wasantwisut, T. Pongcharoen, K. B Bailey, and R. S Gibson
Only a small proportion of anemia in northeast Thai schoolchildren is associated with iron deficiency
Am. J. Clinical Nutrition, August 1, 2005; 82(2): 380 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Joutovsky, J. Hadzi-Nesic, and M. A. Nardi
HPLC Retention Time as a Diagnostic Tool for Hemoglobin Variants and Hemoglobinopathies: A Study of 60000 Samples in a Clinical Diagnostic Laboratory
Clin. Chem., October 1, 2004; 50(10): 1736 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K.-Z. Liu, K. S. Tsang, C. K. Li, R. A. Shaw, and H. H. Mantsch
Infrared Spectroscopic Identification of {beta}-Thalassemia
Clin. Chem., July 1, 2003; 49(7): 1125 - 1132.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Untitled
Bonifacio A. Dy, et al.
Clinical Chemistry Online, 15 Mar 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.